丙型肝炎病毒(hepatitis C virus,HCV)为黄病毒属的单股正链RNA病毒,主要通过血液传播,慢性化程度高。目前的标准治疗是聚乙二醇干扰素(pegylated IFN-α)联合利巴韦林(ribavirin,RBV)。自1989年首次鉴定出HCV以来[1],HCV的干扰素治疗虽然有缓慢的进展,如长效干扰素的使用,但仍无法摆脱其不良反应多、持续病 Hepatitis C virus (HCV) is a single-stranded positive-sense RNA virus of the genus Flavivirus that spreads mainly through the blood and has a high degree of chronicity. The current standard of care is pegylated IFN-α combined with ribavirin (RBV). Since HCV was first identified in 1989 [1], although there has been a slow progression of HCV interferon therapy, such as the use of long-acting interferon, HCV is still unable to escape its adverse reactions and persistent disease